<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Geron-Corporation-US3741631036">Geron Corporation</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/18/3296999/35501/en/Geron-Corporation-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html">Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</a>
    </div>

      <div class="me-0 me-md-5">
        FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options to purchase an aggregate of 333,750 shares of common stock to five newly hired employees as an inducement material to such employees&#39; acceptance of employment with Geron.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Geron-Corporation-US3741631036">Geron Corporation</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/12/3293010/35501/en/First-Real-World-Evidence-Study-of-RYTELO-imetelstat-in-Lower-risk-Myelodysplastic-Syndromes-LR-MDS-to-be-Presented-at-EHA-2026.html">First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026</a>
    </div>

      <div class="me-0 me-md-5">
        Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Geron-Corporation-US3741631036/load_more?page=4">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>